由嵌合抗原受体 (CAR) 重定向的 T 细胞的过继转移在战胜血液恶性肿瘤方面取得了巨大突破。然而，在实体瘤治疗中，由于浸润和扩张不足、过继转移后功能迅速减弱以及严重危及生命的毒性，CAR-T细胞疗法获得的治疗效果有限。为了应对这些挑战，纳米技术的进步利用创新方法来设计更强大的 CAR-T 细胞，降低毒性并增强抗肿瘤活性。为CAR-T细胞配备多功能纳米颗粒可以消除肿瘤区域的免疫抑制信号，增强CAR-T细胞的功能，并减轻其对正常组织的毒性。此外，纳米颗粒介导的 CAR-T 细胞编程有潜力优化制造并降低更广泛实施 CAR-T 细胞疗法的成本。在这篇综述中，我们介绍了 CAR-T 细胞疗法需要克服的障碍，重点介绍了旨在丰富 CAR-T 细胞疗法治疗应用的基于纳米技术的策略，并展望了纳米颗粒辅助 CAR-T 细胞疗法的前景。 T 细胞疗法。© 2024 Wiley periodicals LLC。

The adoptive transfer of T cells redirected by chimeric antigen receptors (CARs) has made a dramatic breakthrough in defeating hematological malignancies. However, in solid tumor treatment, CAR-T-cell therapy has attained limited therapeutic benefits due to insufficient infiltration and expansion, rapidly diminishing function following adoptive transfer, and severe life-threatening toxicities. To address these challenges, advancements in nanotechnology have utilized innovative approaches to devise stronger CAR-T cells with reduced toxicity and enhanced anti-tumor activity. Equipping CAR-T cells with multifunctional nanoparticles can abrogate immunosuppressive signaling in the tumor area, augment the functions of CAR-T cells, and mitigate their toxicity against normal tissues. Additionally, nanoparticle-mediated CAR-T-cell programming has the potential to optimize manufacturing and lower the cost for the broader implementation of CAR-T-cell therapy. In this review, we introduce the obstacles to be surmounted in CAR-T-cell therapy, highlight the nanotechnology-based strategies that aim to enrich the therapeutic applications of CAR-T-cell therapy, and envision the prospect of nanoparticle-assisted CAR-T-cell therapy.© 2024 Wiley Periodicals LLC.